Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC

The requested reference [85282f1321120f8562e40ab385eeb2404f7d9324] no longer exists in our database. It has been replaced by the current reference: [a9e93e05cbf444312bf93d3723dff0cf1b846018]

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This is a single arm, open-label, non-randomized multi-institution phase II trial of a Fc enhanced CTLA4 antibody, vilastobart, in combination with PD-1 antibody, retifanlimab, in patients with BRCA1, BRCA2 or PALB2 deficient pancreatic cancer (PC).
Epistemonikos ID: 3452af9643621ecc99a300dac92e95c3713816de
First added on: Aug 14, 2026